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Abstract
Dithiocarbamates (DTCs) prepared from primary or secondary amines, which incorporated
amino/hydroxyl-alkyl, mono-/bicyclic aliphatic/heterocyclic rings based on the quinuclidine,
piperidine, hydroxy-/carboxy-/amino-substituted piperidine, morpholine and piperazine scaf-
folds, were investigated for the inhibition of a- and b-carbonic anhydrases (CAs, EC 4.2.1.1) of
pharmacologic relevance, such as the human (h) isoform hCA I and II, as well as the
Saccharomyces cerevisiae b-CA, scCA. The yeast and its b-CA were shown earlier to be useful
models of pathogenic fungal infections. The DTCs investigated here were medium potency hCA
I inhibitors (KIs of 66.5–910 nM), were more effective as hCA II inhibitors (KIs of 8.9–107 nM)
and some of them showed excellent, low nanomolar activity against the yeast enzyme,
with inhibition constants ranging between 6.4 and 259 nM. The detailed structure activity
relationship for inhibition of the yeast and human enzymes is discussed. Several of the
investigated DTCs showed excellent selectivity ratios for inhibiting the yeast over the human
cytosolic CA isoforms.
Keywords
b-Class enzyme, carbonic anhydrase,
dithiocarbamate, inhibitor,
Saccharomyces cerevisiae
History
Received 16 December 2014
Revised 15 January 2015
Accepted 15 January 2015
Published online 6 February 2015
Introduction
The primary sulfonamides possessing the general formula
RSO2NH2 (where R may be an aromatic, heterocyclic or aliphatic
moiety, but also an even smaller groups such as OH and NH2)
1–7
dominated the landscape of carbonic anhydrase (CA, EC 4.2.1.1)
inhibitors (CAIs) drug design for 70 years, since the discovery
that such compounds inhibit the enzyme, in the 1940s8–15.
However, recently, new important chemotypes with such proper-
ties emerged, by combining structure-based drug discovery
strategies (X-ray crystallography and fragment-based drug
design) with massive campaigns of screening vast library of
compounds for detecting such an activity16–38. The interest in
CAIs is mainly motivated by their pharmacological properties and
clinical use as diuretics, antiglaucoma, antiobesity or antiepileptic
agents, as well as anticancer agents/diagnostic tools1–3,29–39.
Among the new chemotypes with CA inhibitory properties
ultimately reported, the dithiocarbamates (DTCs) are undoubtedly
among the most interesting ones40–44.
These compounds have been rationally discovered as CAIs
after our report of trithiocarbonate (CS23 , TTC), an inorganic
anion similar to carbonate, as an interesting (milli–micromolar)
CAI45. In the X-ray crystal structure of this anion bound to
hCA II, a monodentate coordination of the inhibitor through one
sulfur atom to the zinc ion from the enzyme active site has been
observed. Furthermore, a hydrogen bond in which another sulfur
of TTC and the OH of Thr199 (a crucial residue for the catalytic
cycle of a-CAs)1–3 were involved, also stabilized the anion when
bound within the enzyme active site. Thus, the CS2 moiety
present in TTC was detected as a new zinc-binding group (ZBG)
for CA inhibition. As DTCs incorporate this ZBG, a first series of
such compounds was prepared and evaluated for their inhibitory
activity against several mammalian, fungal and bacterial CAs by
this group40–44. Several low nanomolar and subnanomolar CAIs
were thus detected against all these enzymes. X-ray crystal
structures were also reported for three DTCs complexed to
hCA II, i.e. compounds A–C (Figure 1)40,41. DTCs A–C inhibited
hCA II with KIs of 25, 41 and 0.95 nM, respectively, and hCA IX
(an isoform involved in cancerogenesis)1,3,5 with KIs of 53, 757
and 6.2 nM, respectively40,41. As seen from Figure 1, the binding
mode of the new ZBG present in these compounds was identical
to that of TTC, with one sulfur coordinated to the metal ion, but
the organic scaffold present in the DTC was observed to make
extensive contacts with many amino acid residues from the active
site. This explains the wide range of inhibitory power of these
derivatives, from the subnanomolar to the micromolar range, for
the entire series of around 30 DTC reported so far40–44.
Interestingly, these compounds are highly water soluble (being
salts), and the DTC C was also effective in vivo as an
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antiglaucoma agent when administered topically directly to the
eye of hypertensive rabbits, a widely used animal model of this
disease41. However, for the moment only one series of DTCs was
reported and investigated as CAIs, and this is the reason why we
extend here the earlier studies40,41, reporting the CA inhibitory
properties of a new series of such compounds against another CA
of interest, the b-class enzyme from the yeast, Saccharomyces
cerevisiae scCA46–48, a model organism of great relevance when
investigating fungal CAs as drug targets49–51.
Materials and methods
Chemistry
The DTCs 1b–21b investigated as scCA inhibitors were prepared
by reaction of the amines 1a–21a with CS2 in the presence of
bases, such as NaOH or KOH52.
CA inhibition
A stopped-flow instrument (SX.18MV-R Applied Photophysics
model) was used for assaying the CA-catalyzed CO2 hydration
activity53. Inhibitor and enzyme were preincubated for 15 min for
allowing the complete formation of the enzyme-inhibitor adduct.
IC50 values were obtained from dose response curves working at
seven different concentrations of test compound (from 0.1 nM to
50mM), by fitting the curves using PRISM (www.graphpad.com)
and non-linear least squares methods, the obtained values repre-
senting the mean of at least three different determinations54. The
inhibition constants (KI) were derived from the IC50 values by using
the Cheng–Prusoff equation, as follows: Ki¼ IC50/(1 + [S]/Km),
where [S] represents the CO2 concentration at which the measure-
ment was carried out andKm the concentration of substrate at which
the enzyme activity is at half maximal. All enzymes used were
recombinant, produced in Escherichia coli as reported earlier13,47.
The concentrations of enzymes used in the assay were: hCA I,
12.0 nM; hCA II, 9.2 nM and scCA, 15.3 nM.
Results and discussion
In the present article, we extended the series of DTCs investigated
earlier40–44, including both primary as well as secondary deriva-
tives, which were obtained in such a way as to explore novel
chemical space. The starting amines (1a–21a) used to synthesize
DTCs 1b–21b reported here (Scheme 1) included N,N-dimethy-
laminoethylenediamine 1a, aminoalcohols with three to five
carbon atoms in their molecule 2a–4a, the bicyclic quinuclidine-
3-amine (both the racemate as well as the R- and S-enantiomeric
DTCs 5b–7b incorporating this scaffold were obtained), piperi-
dine 8a and several of its derivatives with hydroxyl-, carboxy-,
acetamido- and boc-amido functionalities in various positions of
the heterocyclic ring, of types 9a–16a; morpholine and piperazine
derivatives 17a–19a, as well as phenethylamine 20a and its
sulfamoylated derivative, 4-aminoethylbenzenesulfonamide 21a,
a well know CAI which binds to the enzyme through the
sulfamoyl moiety1,3 (Scheme 1). The choice of these scaffolds
was motivated by the fact that the structure–activity relationship
(SAR) for the inhibition of CAs with the DTCs reported earlier7,8
was primarily influenced by the organic scaffold of the inhibitor.
In fact, important differences of activity were observed between
primary and secondary DTCs and between aliphatic or aromatic/
heterocyclic derivatives, respectively40–44. Here we investigated
compounds belonging to these DTCs types, with a variety of
substitution patterns, based on several scaffolds mentioned earlier
(Table 1) among which primary, aliphatic aminoalkyl- or
hydroxyalkyl derivatives (1b–4b); primary, bicyclic, bulky
DTCs (5b–7b), with various stereochemistries; secondary, piperi-
dine, morpholine and piperazine-based DTCs, of types 8b–19b,
for which the lead compound was the morpholine-DTC (com-
pound C) reported earlier40. Indeed, the largest number of the new
DTCs investigated here belongs to this subgroup.
We investigated the CA inhibitory properties of DTCs 1b–21b,
as well as the sulfonamide CAI acetazolamide (AAZ) as standard,
against three relevant CAs, the human (h) cytosolic CA isoforms,
hCA I and II (widespread, off-target enzymes when non-
mammalian CAs should be inhibited) as well as the yeast scCA,
an enzyme belonging to the b-class, which we showed earlier to
be a good model for studying fungal enzymes belonging to this
class13. Indeed, several pathogenic fungi, such as Cryptococcus
neoformans, Candida albicans and C. glabrata, encode b-CAs
homologous to scCA49–51.
The inhibition data of compounds 1b–21b are shown in
Table 1, and the following SAR can be delineated:
(i) The slow isoform hCA I was poorly inhibited by most of the
DTCs investigated here. Few compounds, i.e. 1b, 4b, 18b
and 21b showed inhibition constants ranging between 66.5
and 97.5 nM, being rather efficient hCA I inhibitors. The
remaining derivatives were weaker inhibitors, with inhib-
ition constants ranging between 109 and 910 nM, and were
much less efficient compared to the clinically used
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Figure 1. (A) Structure of DTCs A–C used as lead molecules in the
present study. (B) Electronic density for the adduct of dithiocarbamate B
bound within the active site of hCA II40,41. The zinc ion is shown as the
central sphere and the amino acid residues involved in the binding are
evidenced and numbered (hCA I numbering system)40. The zinc ligands
(except the sulfur from the DTC compound), His94, 96 and 119, are not
shown for the sake of simplicity.
R
N
R1
S
S M
− +
NH
R
R1
MOH, CS2
R1= H or Alkyl
1b-21b1a-21a
Solvent M = Na, K
Scheme 1. Preparation of DTCs 1b–21b, by reaction of amines 1a–21a
with carbon disulfide in the presence of sodium/potassium hydroxide.
DOI: 10.3109/14756366.2015.1010529 Dithiocarbamates with potent inhibitory activity 133
sulfonamide acetazolamide (AAZ, KI of 250 nM), Table 1.
This is a positive feature for a CAI, since hCA I inhibition is
associated with side effects of the systemically or topically
acting sulfonamides, such as AAZ or dorzolamide DZA1,3,5.
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The SAR for the inhibition of this isoform is straightfor-
ward: primary DTCs were the most effective CAIs detected
here (e.g. 1b, 4b and 21b), whereas among the secondary
DTCs only the 3-morpholine-carboxylic acid derivative 18b
was a good inhibitor. Among the hydroxyalkyl-substituted
DTCs 2b–4b, it may be observed that hCA I inhibitory
power was very weak for the compound with three carbon
atoms (2b), increased considerably for its homolog with
four carbon atoms (3b) whereas for the 5-aminopentanol
derivative 4b it reached a good level, with a KI of 66.5 nM
(a410 times increase of the inhibitory power with an
increase of the aliphatic chain from 3 to 5 CH2 groups).
(ii) The physiologically dominant cytosolic isoform hCA II was
more sensitive to inhibition by the compounds investigated
here compared to hCA I. DTCs 1b–21b showed inhibition
constants ranging between 8.9 and 107 nM (AAZ has a KI of
12 nM against this isoform, Table 1). Most of the new DTCs
were medium potency hCA II inhibitors, with KIs ranging
between 30.1 and 80.5 nM. They include the following
DTCs: 1b, 2b, 5b, 7b–12b, 14b, 15b, 17b–19b and 21b.
The most ineffective hCA II inhibitor was the phenethyl
derivative 20b (KI of 107 nM), whereas the sulfamoylated
analog 21b showed an improved efficacy, with a KI of
48.1 nM. The best hCA II inhibitors (KIs in the range of 8.9–
24.3 nM), were 3b, 4b, 6b, 13b and 16b (Table 1). These
effective inhibitors belong to both classes of DTCs, primary
(3b, 4b and 6b) and secondary ones (13b and 16b),
respectively. They incorporate the hydroxyalkyl moieties,
and as for hCA I, the inhibition efficiency increases with the
length of the aliphatic chain from 3 to 5. Another interesting
case was observed for the quinuclidine derivatives. The
racemate 5b was a medium potency inhibitor (KI of
48.7 nM) whereas the R-stereoisomer was 2.57 times a
more effective inhibitor than the racemic compound, with a
KI of 18.9 nM. On the contrary, the S-stereoisomer was the
least effective hCA II inhibitor among these derivatives,
with a KI of 65.9 nM (3.5 times less effective compared to its
antipode 6b). The same behavior was observed for the other
racemate and the two enantiomers investigated here,
the derivatives of nipecotic acid 11b–13b. In this case the
S-enantiomer 13b was 9 times a better hCA II inhibitor
compared to its antipode 12b, whereas the racemate 11b had
an intermediate behavior between the two diastereoisomers,
with a KI of 45.4 nM (Table 1). The position of the other
functional group on the heterocyclic ring on which the CS2
moiety was attached was also an important factor influen-
cing the activity of the heterocyclic DTCs investigated here.
The regiomer DTCs derived from pipecolic, nipecotic and
isonipecotic acids (10b, 11b and 14b, respectively) had
quite different activities: the nipecotic acid derivative 14b
was roughly two times more effective as a hCA II inhibitor
compared to its isomers 10b and 11b. The two amine
derivatives 15b and 16b were also different in their affinity
for hCA II, with the bulkier, Boc derivative 16b being a
potent inhibitor (KI of 13.2 nM), whereas the acetamido one
15b having a weaker activity (KI of 47.9 nM). All these data
show that rather small differences in the scaffold of these
DTCs lead to quite different inhibitory activities, probably
due to the fact that as explained earlier, the scaffold of the
inhibitor participates in many interactions with amino acid
residues from the CA active site, which may stabilizing or
in case of clashes, weaken the inhibitory power of the
corresponding compound.
(iii) scCA was also effectively inhibited by DTCs 1b–21b, which
showed inhibition constants in the range of 6.4–278 nM. The
SAR for the inhibition of the yeast enzyme is more
complicated compared to the ones outlines above for the
inhibition of the two human cytosolic isoforms. Thus, two
DTCs, the quinuclidine derivatives 5b–7b and the bulkier
derivative 19b, behaved as weak scCA inhibitors, with KIs
of 181–278 nM. It may be observed that all of them are
rather bulky, sterically hindered compounds which probably
cannot easily accommodate within the scCA active site
which is a long and not very wide channel48–50. Another
group of DTCs, among which 1b–3b, 15b, and 20b, 21b,
similarly to AAZ (KI of 82.6 nM) showed medium potency
Table 1. hCA I, II and scCA inhibition data with DTCs 1b–21b and
acetazolamide (AAZ, 5-acetamido-1,3,4-thiadiazole-2-sulfonamide) as
standard drug, by a stopped-flow CO2 hydrase assay.
KI (nM)*
No R R1 hCA I hCA II scCA
1b Me2N(CH2)2 H 85.9 35.8 82.4
2b HO(CH2)3 H 706 41.7 72.5
3b HO(CH2)4 H 295 24.3 41.4
4b HO(CH2)5 H 66.5 17.3 20.5
5b
N
H 494 48.7 216
6b (R)
N
H 240 18.9 278
7b (S)
N
H 615 65.9 181
8b –(CH2)5– 252 30.1 13.8
9b –(CH2)3–CH(OH)CH2– 428 60.7 19.1
10b –(CH2)4–CH(COONa)– 485 80.1 10.5
11b –(CH2)3–CH(COONa)CH2– 290 45.4 18.7
12b (R) –(CH2)3–CH(COONa)CH2– 496 80.5 9.1
13b (S) –(CH2)3–CH(COONa)CH2– 109 8.9 23.8
14b –(CH2)2–CH(COONa)(CH2)2– 337 78.7 6.4
15b –(CH2)3–CH(NHAc)CH2– 910 47.9 45.9
16b –(CH2)3–CH(NHBoc)CH2– 683 13.2 24.1
17b –CH(Me)CH2–O–(CH2)2– 434 60.2 16.5
18b –CH(COONa)CH2–O–(CH2)2– 84.7 78.5 18.4
19b –(CH2)2N(CH2CONHC6H11)(CH2)2– 415 67.2 259
20b Ph(CH2)2 H 425 107 51.5
21b H2NO2SC6H4(CH2)2 H 97.5 48.1 78.9
AAZ – – 250 12 82.6
*Mean from three different assays. Errors were in the range of ±5–10% of
the reported values (data not shown).
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activity against scCA, with KIs ranging between 41.1 and
82.4 nM (Table 1). These compounds incorporate the amino/
hydroxyalkyl chains with two to four carbon atoms (1b–3b),
arylalkyl chains (as in 20b and 21b) or the acetamido-
piperidine scaffold present in 15b (which is in fact an
outlier, as all other piperidine, and morpholine DTCs
investigated here showed a better inhibition profile against
scCA compared to 15b. Indeed, the most effective scCA
inhibitors were just these derivatives, i.e. 8b–14b, 16b–18b
(KIs of 6.4–24.1 nM) together with the hydroxyl-pentyl
DTC 4b (KI of 20.5 nM). Thus, for the primary aliphatic
derivatives 2b–4b, scCA inhibitory activity increased with
the length of the carbon atoms chain. For the piperidine
derivatives activity was better when another functional
group (such as OH, COOH, BocNH) was attached on the
ring (compared to the parent derivative of the series, 8b), but
the substitution pattern and the stereochemistry were factors
which influenced the activity considerably. For example the
nipecotic acid 11b–13b are again of interest to analyze:
the R-enantiomer 12b was highly effective (KI of 9.1 nM,
the same potency as the hydroxyl-substituted piperidine
10b), whereas the S-enantiomer 13b had a 2.5 times lower
activity (KI of 23.8 nM). The best scCA inhibitor was
however the isonipecotic acid derivative 14b, which had a
KI as low as 6.4 nM, being the best scCA inhibitor reported
to date. The morpholine DTCs 17b and 18b also had a good
scCA inhibition profile, with KIs of 16.5–18.4 nM. It should
be noted that many DTCs investigated here were several
times better scCA inhibitors compared to AAZ, a clinically
used sulfonamide inhibitor, but a moderate scCA inhibitor.
Another important feature, some of the DTCs investigated
here showed selectivity for the inhibition of the yeast over
the human enzymes. Examples of such derivatives are
8b–12b, 14b, 17b and 20b. In the case of 14b, the
selectivity ratio for inhibiting scCA over hCA I was of
52.6 and of inhibiting scCA over hCA II of 12.3, making this
derivative one of the most selective inhibitor for the yeast
over the human CA isoforms.
Conclusion
We investigated the inhibition of two human, off-target CA
isoforms and the yeast b-class enzyme scCA with a series of
DTCs prepared both from primary and secondary amines and
carbon disulfide, in the presence of strong bases. These DTCs
incorporated amino/hydroxyl-alkyl, mono-/bicyclic aliphatic/het-
erocyclic rings based on the quinuclidine, piperidine, hydroxy-/
carboxy-/amino-substituted piperidine, morpholine and pipera-
zine scaffolds. The investigated compounds were medium
potency hCA I inhibitors (KIs of 66.5–910 nM), they were more
effective as hCA II inhibitors (KIs of 8.9–107 nM), and some of
them showed excellent, low nanomolar activity against the yeast
enzyme, with inhibition constants ranging between 6.4 and
259 nM. The detailed structure activity relationship for inhibition
of the yeast and human enzymes is discussed. Several of the
investigated DTCs showed excellent selectivity ratios for inhibit-
ing the yeast over the human cytosolic CA isoforms.
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